DRUG
Al18F-octreotide
Al18F-octreotide I was injected into the patients before the PET/CT scans
Status
Recruiting
Phase
Phase 2 / Phase 3
Enrollment
400
Locations
1
Results
Not posted
Publications
0
Study summary
This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with SSTR positive tumors
Octreotide is an artificial replacement for the natural growth hormone inhibitor in humans. It is a small peptide hormone consisting of 14 amino acids and is widely distributed in neuroendocrine cells, with the highest density in the brain, peripheral neurons, endocrine pancreas and gastrointestinal tract. Under pathological conditions, some tumour cells show overexpression of growth inhibitory receptors, such as endocrine tumours of the pancreas, pituitary adenomas, pheochromocytomas, paragangliomas, carcinoid tumours, medullary thyroid carcinomas, small cell lung carcinomas Hepatocellular carcinoma, and meningioma. Therefore, the sensitivity and specificity of octreotide imaging is high. This study will provide a visual, reproducible and non-invasive imaging method for the diagnosis of SSTR positive tumors through Al18F-octreotide PCT/CT imaging, providing an intuitive and clear imaging basis for clinical diagnosis, differential diagnosis and treatment, contributing to the development of medicine and science in the field of positron imaging.
Interventions
DRUG
Al18F-octreotide I was injected into the patients before the PET/CT scans
Timeline
First posted
Mar 1, 2023
Study start
Dec 20, 2022
Primary completion
Dec 20, 2028
Study completion
Dec 20, 2029
Results posted
Not reported
Registry updated
Apr 6, 2026
Outcomes
Diagnostic value
Time frame · through study completion, an average of 1 year]
Sensitivity and Specificity of Al18F-octreotide PET/CT for SSTR positive tumors
Not reported in the indexed record.
Eligibility
Inclusion Criteria: * Patients with suspected or clearly diagnosed SSTR positive tumors * signed written consent. * Willing and able to cooperate with all projects in this study. Exclusion Criteria: * pregnancy; * breastfeeding; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Study locations
China. Showing up to 24 locations stored in the fast local snapshot.
National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Chao Yang, China
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
National Cancer Institute (NCI) · Colorectal Neuroendocrine Tumor G1 · Gastric Neuroendocrine Tumor G1
Phase 3
Active, not recruiting
427
2026-07
Camurus AB · Gastro-enteropancreatic Neuroendocrine Tumor
Phase 3
Active, not recruiting
332
2026-07
Debiopharm International SA · Acromegaly
Phase 3
Recruiting
119
2026-07
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · ACTH · Cushing's Syndrome
Phase 2
Recruiting
80
2026-07
M.D. Anderson Cancer Center · Neuroendocrine Carcinoma · Islet Cell Carcinoma
Phase 2
Completed
67
2026-07
Columbia University · Hyperinsulinemia · Insulin Resistance
Phase 1
Recruiting
25
2026-07
Camurus AB · Acromegaly
Not applicable
Recruiting
200
2026-06
Triastek (Shanghai) Limited · Acromegaly
Phase 1
Not yet recruiting
18
2026-06
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.